timothy sykes logo
Oscar Health FY25 Revenue Boosts Forecast Amid Mixed Q2 Results Thumbnail
ADD US ONG Google News

Oscar Health FY25 Revenue Boosts Forecast Amid Mixed Q2 Results

JACK KELLOGG•UPDATED AUG. 16, 2025, 12:37 PM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

Oscar Health Inc.’s stocks have been trading up by 7.63 percent amid positive sentiment from strategic partnerships in healthcare.

Healthcare industry expert:

Analyst sentiment – neutral

Oscar Health Inc. (OSCR) displays a mixed market position characterized by growth in revenue juxtaposed with substantial operational challenges. The company reported a revenue of $9.18 billion and achieved a revenue per share of $41.15. Despite this, profit metrics show significant underperformance, with a pretax profit margin of -6% and an ROE of -26.44%. The company’s assets, notably with an asset turnover of 1.9, indicate efficient use, yet profitability margins like EBIT margin maintain a concerning negative trend. Financially, Oscar shows robust free cash flow of $499.79 million, but continued net losses raise questions about sustainable profitability. Overall, OSCR’s fundamentals highlight the company’s capacity for revenue growth but underline glaring inefficiencies in its cost structure and profitability efforts.

Technically, Oscar Health’s recent price action illustrates a neutral to slightly bullish trend. The stock has fluctuated between $14.92 and $15.85, showing moderately increased buying interest towards the later part of the session when prices reached a weekly high closure at $15.83. This hints at potential recovery towards mid-term resistance levels around $16.00 if sustained by bullish momentum. However, the consistent volume spikes coincide with dips, suggesting cautious market sentiment. Investors might consider buying on dips around the $14.80 support range, with a tight stop-loss below $14.60 to mitigate downside risk. Monitoring for a confirmed breakout above $15.90 could potentially validate a bullish trend continuation strategy, aligning with short-term technical bullish patterns.

Oscar Health’s future trajectory is underscored by strategic focuses that anticipate revenue growth, albeit intermixed with challenges evident in the recent widening of losses. The revised fiscal year 2025 revenue projections between $12.0B and $12.2B signify robust growth sentiment, standing above previous forecasts, yet the company still foresees operation losses from ($300K) to ($200K). The analyst community offers divergent views, exemplified by Piper Sandler’s adjusted price target to $13, maintaining neutrality. While Oscar faces steep industry competition in the healthcare insurance sector, its reaffirmed revenue growth outlook offers potential long-term appeal. Technical resistance sits around $16.00, whereas support is pegged near $14.80. Thus, the outlook remains cautiously optimistic, with a gradual path to profitability anticipated by 2026.

Candlestick Chart

Weekly Update Aug 11 – Aug 15, 2025: On Saturday, August 16, 2025 Oscar Health Inc. stock [NYSE: OSCR] is trending up by 7.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Oscar Health has made bold strides in adjusting its strategy and financial forecasts, aiming for a substantial revenue boost in FY25. Initially set between $11.2B and $11.3B, the new revenue projections now range from $12.0B to $12.2B—this formidable leap reflects management’s confidence in their market positioning and operational prowess. The company reported a slight miss in Q2 revenue, coming in at $2.86B against analyst estimates of $2.91B. However, it didn’t overshadow the reassurance brought by solidifying operational loss forecasts, slated to come in narrower than initially predicted.

More Breaking News

The company remains on a trajectory toward profitability by 2026. This forward-thinking strategy is evident through adjustments in the Medical Loss Ratio and SG&A Expense Ratio, showcasing improved fiscal management. A revised guidance affirms robust fiscal health, despite navigating a competitive and evolving healthcare landscape. Earnings per share suffered, recording at -0.89 against the backdrop of ambitious revenue targets. Yet, Oscar Health remains resolute, committed to carving a profitable path ahead.

Conclusion

Oscar Health’s evolving financial journey is marked by strong revenue forecasting juxtaposed with an ambition to curb losses in the face of current fiscal challenges. Its strategic revenue adjustments reflect an assertive move to capitalize on market opportunities and sustain growth. Traders are poised on a notable tapestry—envisioning profitability in 2026 while evaluating risk against the bullish revenue outlook. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” As Oscar Health navigates this pivot from expanded losses to anticipated gains, its market position in the healthcare insurance realm stands out as a beacon for both bold expectation and strategic recalibration.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading OSCR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”